Compare MMED & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMED | OBDC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.6B |
| IPO Year | 2025 | 2015 |
| Metric | MMED | OBDC |
|---|---|---|
| Price | $17.84 | $10.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $25.00 | $13.17 |
| AVG Volume (30 Days) | ★ 11.8M | 3.6M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 12.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $3,102,000,000.00 | N/A |
| Revenue This Year | $10.84 | N/A |
| Revenue Next Year | $8.39 | N/A |
| P/E Ratio | ★ N/A | $129.25 |
| Revenue Growth | ★ 14.25 | N/A |
| 52 Week Low | $10.65 | $9.82 |
| 52 Week High | $24.43 | $13.58 |
| Indicator | MMED | OBDC |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 40.81 |
| Support Level | $14.70 | $9.82 |
| Resistance Level | $17.86 | $11.37 |
| Average True Range (ATR) | 0.84 | 0.18 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 33.02 | 42.98 |
While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.